Company intelligence / Profile preview

Curiteva

Huntsville, Alabama, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Curiteva has achieved commercial adoption of its Inspire 3D printed trabecular PEEK interbody fusion platform for spine surgery, surpassing 2,000 patient procedures and over 3,700 implants since launch in July 2023. The company reports strong early clinical outcomes showing rapid bone bridging and integration on radiography, with further commercial expansion in both cervical and lumbar fusion applications. Clinical data highlights enhanced osseointegration and patient outcomes, supported by a proprietary manufacturing process and bioactive nano-surface technology.

Therapeutic areas: OtherNeurologyRheumatology
Modalities: Device3D Printed Trabecular PEEK ImplantSolid PEEK ImplantTitanium Implant
Industry: Implantable Medical Devices

Partnerships

Promimic

Beyond the preview

Go deeper on Curiteva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curiteva.

Explore the full profile